Download the appMore options
PisaczekSearch
文AEN-US
DiseasesStudies updated this month

Blood pressure pills — do they treat the cause or just the measurement result?

Sources: 11 · Article: 11 407 characters ↓

What do Natural Therapy Specialists write?

Jerzy Jaśkowski

Blood pressure measurement is used to assess a patient’s condition, and an upper-arm measurement is indicated as the correct method.

„The formula from this law makes it possible to assess a patient’s condition by measuring blood pressure. However, we must remember that only an upper-arm measurement is correct. Wrist measurements, which are easier to take, provide only an approximate value. To monitor a patient’s blood pressure, we should also measure it on the upper arm, and at different times of day.”Wzór z tego prawa pozwala na ocenę stanu chorego poprzez pomiar ciśnienia krwi. Musimy jednak pamiętać, że tylko pomiar ramienny jest prawidłowy. Pomiary nadgarstkowe, łatwiejsze do przeprowadzenia, dają tylko wartość orientacyjną. W celu kontrolowania u chorego wartości ciśnienia powinniśmy dokonywać pomiaru ciśnienia także na ramieniu, w dodatku o różnej porze dnia.
Andrzej Frydrychowski

The medicines used block angiotensin receptors in blood vessels, while the author identifies a higher level of regulation as the place where a therapeutic effect should be achieved.

„A therapeutic effect could be achieved at the highest level of regulation (for example, the vasomotor centers), rather than at the final, effector level of treatment—that is, by blocking angiotensin receptors in blood vessels with the medicines used. Restoring impaired autoregulation could naturally help reverse many disease-related changes and, in many cases, eliminate the need for medication or greatly reduce its use.”Efekt leczniczy uzyskalibyśmy na najwyższym piętrze regulacji (np. ośrodki naczynioruchowe), a nie ostatnim piętrze leczenia (efektorowym), to jest na poziomie blokady receptorów angiotensyny w naczyniach krwionośnych poprzez stosowane leki. Przywrócenie zaburzonej autoregulacji mogłoby przyczynić się w naturalny sposób do cofnięcia wielu zmian chorobowych i w wielu przypadkach wyeliminować lub znacznie zmniejszyć stosowanie leków.
Andrzej Frydrychowski

In the author’s view, restoring impaired autoregulation could reverse some changes and reduce the need for medication.

„Restoring impaired autoregulation could naturally help reverse many disease-related changes and, in many cases, eliminate the need for medication or greatly reduce its use. The text comes from excerpts of a book on auriculotherapy, in whose preparation a physician took part.”Przywrócenie zaburzonej autoregulacji mogłoby przyczynić się w naturalny sposób do cofnięcia wielu zmian chorobowych i w wielu przypadkach wyeliminować lub znacznie zmniejszyć stosowanie leków. Tekst pochodzi z fragmentów książki o aurikuloterapii, w której opracowaniu brał udział lek.
Prof. Klaus F. Kopp

Prof. Klaus F. Kopp claims that typical medicines block hormones linked to high blood pressure but do not treat the bicarbonate deficiency he describes.

„The prescribed medicine therefore usually consists only of pharmacological hormone antagonists against the hormones of the renin-angiotensin-aldosterone group. Unfortunately, the bicarbonate deficit is never treated. Bicarbonate replacement is usually very effective in lowering blood pressure to the normal range, provided that no significant secondary damage from hypertension is already present in the body, for example.”The prescribed medicine therefore usually comprises only the pharmacological hormone-antagonists against the hormones of the renin-angiotensin-aldosteron-group Unfortunately, the bicarbonate-deficit is never being treated. Substitution of bicarbonate is usually very effective in lowering the blood pressure into the normal range provided that no significant secondary damages of hypertension are already present in the body e.g.
Prof. Klaus F. Kopp

Prof. Klaus F. Kopp presents bicarbonate deficiency as an unresolved cause and bicarbonate replacement as a way to treat hypertension.

„The bicarbonate deficiency is never corrected. Sodium bicarbonate would be the most effective vasodilating substance physiologically. In fact, consistent bicarbonate replacement that permanently replenishes bicarbonate stores can effectively treat hypertension; this brings about a state of “alkalotic volume contraction.””Nur der Bikarbonat-Mangel wird nirgendwo beseitigt. Natrium-Bikarbonat wäre dabei die physiologisch am besten wirkende vasodilatatorische Substanz. Tatsächlich gelingt es durch konsequente Bikarbonat-Substitution mit dauerhafter Sättigung der Bikarbonat-Speicher eine Hypertonie wirksam zu therapieren, der Zustand der „alcalotic volume-contractions“ wird hierdurch herbeigeführt.

What does scientific research from PubMed · Europe PMC say?

We selected 4 studies with the best, positive results. This is a selection, not a full review of all research.

Total number of studies on this topic in PubMed: 43 040.

Aim of the study: To summarize recent evidence on the effectiveness and safety of antihypertensive fixed-dose combination (FDC) medications, and to describe the facilitators and barriers to implementing FDCs in US clinical practice.

Results: Recent clinical practice guidelines include the use of FDCs to treat high blood pressure. Clinical trials in recent years support the use of antihypertensive FDCs, including low-dose triple- and quadruple-therapy FDCs. Starting treatment with a low-to-standard-dose dual-therapy FDC resulted in better blood pressure control than starting with standard-dose monotherapy, and triple-therapy FDCs produced better blood pressure control rates than dual-therapy FDCs. Retrospective cohort studies showed that FDCs are associated with better medication adherence, less clinical inertia, shorter time to blood pressure control, and improved cardiovascular outcomes. We also discussed barriers and factors that support wider implementation of antihypertensive FDCs in clinical practice. FDC treatment for hypertension is not commonly used, despite historical and recent data supporting its effectiveness, safety, and benefits.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Valsartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and a diuretic, indicated for patients with hypertension as initial therapy and for those whose condition is not controlled with monotherapy. The aim was to evaluate the pharmacokinetic, pharmacodynamic, and clinical effectiveness of valsartan/hydrochlorothiazide in treating hypertension and its effects on other cardiovascular outcomes.

Results: Valsartan/hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. Compared with amlodipine, valsartan/hydrochlorothiazide had a similar rate of the combined outcome of morbidity and mortality. Valsartan/hydrochlorothiazide has also been studied in specific patient groups, such as people with diabetes, people with obesity, older adults, Black people with hypertension, and people with hypertension and additional cardiovascular risk factors; it has been shown to be effective in these groups. Valsartan/hydrochlorothiazide has been shown to be an effective fixed-dose combination antihypertensive medicine that is well tolerated and has few side effects.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Congenital adrenal hyperplasia (CAH) due to 17α-hydroxylase/17,20-lyase deficiency (17OHD) is a rare form of CAH characterized by cortisol deficiency, impaired sex steroid production, and excess deoxycorticosterone (DOC), resulting in low-renin hypertension and hypokalemia.

Results: Despite treatment escalation, DOC and pregnenolone levels remained elevated and blood pressure remained poorly controlled. After crinecerfont 100 mg twice daily was started, blood pressure improved to 120-130/80-90 mmHg, plasma renin activity increased, and DOC and pregnenolone concentrations returned to normal without any further increase in glucocorticoids. Clinical and biochemical improvements were sustained during 12 months of follow-up. This case is the first reported use of crinecerfont in 17OHD and suggests that CRF1 receptor antagonism may offer a new treatment option for treatment-resistant hypertension driven by ACTH-dependent mineralocorticoid excess.

Money for the studygovernment, public institutions · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Do the authors have ties to companies?yes — the authors reported it
Did a manufacturer help with the study?YES
Type of studyother
Participants1

“Not stated” does not mean nobody paid — the database does not always record it.

Aim of the study: Blood pressure (BP) control among people with hypertension remains inadequate. This study aims to assess achievement of BP targets among people prescribed antihypertensive medicines, examine medication nonadherence, and identify demographic factors associated with achieving targets and with medication nonadherence in this population.

Results: Antihypertensive medicines were prescribed to 567 participants. Based on imputed data, 63.8% of these participants achieved the 2013 BP target. The mean medication nonadherence score was 1.6 (SE ± 0.06), with 34.8% of participants being nonadherent. Taking multiple antihypertensive pills was associated with a lower likelihood of achieving BP targets. In the sensitivity analysis, 38.4% achieved the 2024 BP target, and in the multivariable analysis, being overweight or obese was associated with not achieving the 2024 targets. The study highlights the gap between BP targets in guidelines and achievement of these targets in real-world practice. It identified key patient and medication factors that could guide efforts to improve BP target achievement. Trial Registration: ClinicalTrials.gov identifier: NCT03191227.

Money for the studycompany together with others · Novartis Ireland Ltd, Health Research Board, Ministry of Higher Education and Scientific Research
Do the authors have ties to companies?no — the authors say so
Did a manufacturer help with the study?YES
Type of studyobservation of people
Participants567

“Not stated” does not mean nobody paid — the database does not always record it.

What do orthomolecular medicine doctors write?

Orthomolecular Medicine News Service
„Among the 480 people with hypertension who increased their vitamin D3 intake, mean systolic blood pressure fell from 156 mm to 138 mm, and mean diastolic blood pressure fell from 96 mm to 84 mm, regardless of whether they were taking blood pressure medication. As a result, 71% of those who had hypertension at the start of the trial no longer had hypertension at the end. There was no significant reduction in blood pressure among people who did not have hypertension.”For the 480 hypertensives who increased their vitamin D3 intake, the mean systolic blood pressure dropped from 156 mm to 138 mm and the mean diastolic blood pressure dropped from 96 mm to 84 mm, both independent of whether they were taking blood pressure medication. As a result, 71% of those hypertensive at baseline were no longer hypertensive at the end of the trial. There was no significant reduction in blood pressure for non-hypertensives.
Orthomolecular Medicine News Service
„Burke B, Neuenschwander R, Olson R (2001) Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. Southern Medical Journal 94:1112-1117. Rosenfeldt F, Hilton D, Pepe S, Krum H (2003) Systematic review of the effect of coenzyme Q10 on physical exercise, hypertension, and heart failure. Biofactors 18:91-100. Rosenfeldt F, Haas S, Krum H et al.”Burke B, Neuenschwander R, Olson R (2001) Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. Southern Medical Journal 94:1112-1117. Rosenfeldt F, Hilton D, Pepe S, Krum H (2003) Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 18:91-100. Rosenfeldt F, Haas S, Krum H et al.
Orthomolecular Medicine News Service
„ADHD Drugs Are Dangerous Depending on which ADHD drug is being taken, side effects of overdose include mydriasis, tremors, anxiety, agitation, hyperreflexia, headache, gastrointestinal upset, combative behavior, confusion, hallucinations, delirium, dizziness, dystonia, insomnia, paranoia, movement disorders, tachycardia, hypertension, seizures, and yes, even hyperactivity, the very condition an ADHD drug is supposed to be treating. Oh, and they can kill you (6,7). Even if “fatalities are rare” (7), I imagine this brings little comfort to parents.”ADHD Drugs Are Dangerous Depending on which ADHD drug is being taken, side effects of overdose include mydriasis, tremors, anxiety, agitation, hyper-reflexia, headache, gastrointestinal upset, combative behavior, confusion, hallucinations, delirium, dizziness, dystonia, insomnia, paranoia, movement disorders, tachycardia hypertension, seizures, and yes, even hyperactivity, the very condition an ADHD drug is supposed to be treating. Oh, and they can kill you (6,7). Even if "fatalities are rare" (7), I imagine this brings little comfort to parents.

Sources (11)

Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.